Sofinnova Partners
Sofinnova Partners is a European life sciences venture capital firm founded in 1972 that invests from seed to later stage with a focus on healthcare and sustainability.
- Type
- Venture capital firm
- Website
- https://sofinnovapartners.com/
- Investment focus
- healthcare, sustainability, biopharma, medtech
- Stages
- seed, early stage, later stage
About
Sofinnova Partners says it is a European life sciences venture capital firm founded in 1972. Its site says it has backed more than 500 companies and manages over €4 billion, investing from seed to later stage with a focus on healthcare and sustainability. The contact page lists offices in Paris, Milan and London, so no single headquarters city is stored.
Sofinnova Partners co-led Alethio Therapeutics' $90 million Series A with RA Capital Management, announced on 2026-11-05.
This page is not indexed by search engines yet. It is promoted once it meets the quality gate for investor pages: a description from the firm's own website, a headquarters city and at least two two-sourced rounds on this site.
Funding rounds on RaiseTrack
| Company | Round | Date | Role |
|---|---|---|---|
| Alethio Therapeutics | Series A 2026 | 2026-11-05 | lead |
Sources
Last verified:
- https://sofinnovapartners.com/
Type: official investor website. Accessed 2026-11-05.
Sofinnova Partners home page, read 2026-11-05. Says founded in 1972, has backed more than 500 companies, and has over €4 billion under management. Says it invests across the life sciences value chain from seed to later stage with a focus on healthcare and sustainability. - https://sofinnovapartners.com/contact
Type: official investor website. Accessed 2026-11-05.
Sofinnova Partners contact page, read 2026-11-05. Lists offices in Paris, Milan and London. No single headquarters city is stored. - https://alethiotherapeutics.com/alethio-therapeutics-raises-90-million-67-million-in-oversubscribed-series-a-financing-to-advance-a-new-generation-of-therapies-for-myeloproliferative-neoplasms/
Type: company announcement. Accessed 2026-11-05.
Alethio Therapeutics release, 5 November 2026. Names Sofinnova Partners as a co-lead of the $90 million Series A. - https://buttondown.com/raisetrack/archive/raise-track-update-2026-11-05/
Type: other verified public source. Accessed 2026-11-05.
Raise Track Update for 2026-11-05. Section 2 deep-dive on Sofinnova Partners. Names it as co-lead of Alethio Therapeutics' $90M Series A.